[go: up one dir, main page]

AR056459A1 - Derivados de 3-sulfonililindazol para el tratamiento de trastornos del snc afectados por el receptor 5-ht6 - Google Patents

Derivados de 3-sulfonililindazol para el tratamiento de trastornos del snc afectados por el receptor 5-ht6

Info

Publication number
AR056459A1
AR056459A1 ARP060103550A ARP060103550A AR056459A1 AR 056459 A1 AR056459 A1 AR 056459A1 AR P060103550 A ARP060103550 A AR P060103550A AR P060103550 A ARP060103550 A AR P060103550A AR 056459 A1 AR056459 A1 AR 056459A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
aryl
heteroaryl group
alkyl
cycloalkyl
Prior art date
Application number
ARP060103550A
Other languages
English (en)
Inventor
Kevin Liu
Cristina Grosanu
Hassan Mahmoud Elokdah
Geraldine Ruth Mcfarlane
Jennifer Rebecca Lo
Albert J Robichaud
Alexander Alexei Greenfield
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR056459A1 publication Critical patent/AR056459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), caracterizado porque: X es O, S, NR, CH2, CO, CH2O, CH2S, CH2NR, CH2CO, CONR o NRCO; n es 0 o un entero entre 1, 2, 3, 4, 5, o 6; R es H o un grupo alquilo opcionalmente sustituido; R1 es H o un grupo alquilo, cicloalquilo, arilo o heteroarilo cada uno sustituido opcionalmente; R2 es un grupo alquilo, cicloalquilo, arilo o heteroarilo opcionalmente sustituido o un sistema de anillo bicíclico o tricíclico de 8- 13- miembros opcionalmente sustituido que tiene un átomo N en un cabezal de puente y opcionalmente contiene 1, 2 o 3 heteroátomos adicionales seleccionados entre N, O o S; R3 y R4 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido; R5 es H, COR12 o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido; R6 es H o un grupo alquilo opcionalmente sustituido; p es 0 o un entero ente 1 o 2; R7 es halogeno, CN, OR8, CO2R9, CONR10R11, o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido; m es 0 o un entero entre 1, 2 o 3; R8 es H, COR12, o un grupo alquilo, alquenilo, alquinilo, arilo o heteroarilo cada uno opcionalmente sustituido; R9 es H o a un grupo alquilo C1-6, arilo o heteroarilo cada uno opcionalmente sustituido; R10 y R11 son cada uno independientemente cada uno H o un grupo alquilo opcionalmente sustituido; y R12 es un grupo alquilo C1-6, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo opcionalmente sustituido; o un estereoisomero de ellos o una sal farmacéuticamente aceptables de ella.
ARP060103550A 2005-08-15 2006-08-14 Derivados de 3-sulfonililindazol para el tratamiento de trastornos del snc afectados por el receptor 5-ht6 AR056459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70831705P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
AR056459A1 true AR056459A1 (es) 2007-10-10

Family

ID=37315656

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103550A AR056459A1 (es) 2005-08-15 2006-08-14 Derivados de 3-sulfonililindazol para el tratamiento de trastornos del snc afectados por el receptor 5-ht6

Country Status (21)

Country Link
US (1) US7790751B2 (es)
EP (1) EP1915348A1 (es)
JP (1) JP2009504738A (es)
KR (1) KR20080034497A (es)
CN (1) CN101291913A (es)
AR (1) AR056459A1 (es)
AU (1) AU2006291414A1 (es)
BR (1) BRPI0614341A2 (es)
CA (1) CA2619309A1 (es)
CR (1) CR9733A (es)
EC (1) ECSP088176A (es)
GT (1) GT200600374A (es)
IL (1) IL189416A0 (es)
MX (1) MX2008002158A (es)
NO (1) NO20080553L (es)
PE (1) PE20070373A1 (es)
RU (1) RU2008103700A (es)
SV (1) SV2008002653A (es)
TW (1) TW200800913A (es)
WO (1) WO2007032833A1 (es)
ZA (1) ZA200801524B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
ATE495153T1 (de) * 2006-11-09 2011-01-15 Hoffmann La Roche Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
EP2158195A1 (en) 2007-05-15 2010-03-03 Wyeth LLC 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
ES2568262T3 (es) * 2009-04-23 2016-04-28 Abbvie Inc. Moduladores de receptores de 5-HT y sus métodos de uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813926A (pt) * 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
WO2001005758A2 (en) * 1999-07-15 2001-01-25 Nps Allelix Corp. Indoles and indazoles for the treatment of migraine
JP4307073B2 (ja) * 2000-12-22 2009-08-05 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物
BR0209056A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
EA200301143A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
CN1922150A (zh) * 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物

Also Published As

Publication number Publication date
JP2009504738A (ja) 2009-02-05
TW200800913A (en) 2008-01-01
ZA200801524B (en) 2010-04-28
ECSP088176A (es) 2008-04-28
GT200600374A (es) 2007-03-29
AU2006291414A1 (en) 2007-03-22
RU2008103700A (ru) 2009-09-27
US7790751B2 (en) 2010-09-07
MX2008002158A (es) 2008-04-19
EP1915348A1 (en) 2008-04-30
BRPI0614341A2 (pt) 2011-03-29
CR9733A (es) 2008-04-02
SV2008002653A (es) 2008-04-11
KR20080034497A (ko) 2008-04-21
PE20070373A1 (es) 2007-04-04
NO20080553L (no) 2008-04-23
US20070054896A1 (en) 2007-03-08
CN101291913A (zh) 2008-10-22
IL189416A0 (en) 2008-06-05
WO2007032833A1 (en) 2007-03-22
CA2619309A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
SV2017005384A (es) Compuestos aminopirimidinilo
MXPA06002880A (es) Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes.
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
AR040048A1 (es) Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
CO5640136A2 (es) Derivados de hexahidropiridoisoquinolinas inhibidores de dpp-iv y composiciones farmaceuticas que los contienen
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
AR075731A1 (es) Derivados heterociclicos de bencimidazoles, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento del virus sincicial respiratorio(vsr).
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR038401A1 (es) Derivados de indazol substituidos como agentes terapeuticos
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR068521A1 (es) Derivados heterociclicos triciclicos
AR069691A1 (es) Derivados ciclopropilamina
AR057981A1 (es) Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure